Meeting
2017 Gastrointestinal Cancers Symposium
Nab-paclitaxel and gemcitabine in advanced pancreatic cancer: The one-year experience of the National Cancer Institute of Naples.
Authors
Alessandro Ottaiano
Department of Abdominal Oncology, National Cancer Institute"G Pascale" Foundation, Naples, Italy, Naples, Italy
Alessandro Ottaiano , Monica Capozzi , Chiara De Divitiis , Claudia Von Arx , Elena Di Girolamo , Guglielmo Nasti , Ernesta Cavalcanti , Fabiana Tatangelo , Giovanni Romano , Salvatore Tafuto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 497)
DOI
10.1200/JCO.2017.35.4_suppl.497
Abstract #
497
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma.
First Author: Vincent J. Picozzi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.
First Author: Vincent J. Picozzi
Poster
2019 Gastrointestinal Cancers Symposium
Impact of new chemotherapy regimens on the treatment landscape and survival of advanced pancreatic cancer (PAC) patients (pts).
First Author: Markus Kieler
Poster
2017 ASCO Annual Meeting
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Philippa Corrie